Genmab A/S Dkk (GNMSF) 74.0898 $GNMSF
Major Shareholder Announcement
GlobeNewswire - Wed Feb 04, 4:58PM CST
Company Announcement
GEN: 8.63 (+0.20)
Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)
GlobeNewswire - Wed Feb 04, 6:05AM CST
Company Announcement
GEN: 8.63 (+0.20)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
How Genmab (GNMSF) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Genmab is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Fri Dec 12, 12:59PM CST
Genmab A/S (Copenhagen:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen"
, triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer.
GEN: 8.63 (+0.20)
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas
GlobeNewswire - Thu Dec 04, 12:36AM CST
Company Announcement
GEN: 8.63 (+0.20)
Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma
GlobeNewswire - Mon Nov 24, 7:53AM CST
Company Announcement
GEN: 8.63 (+0.20)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.22 (+0.40), INO: 6.80 (-0.15), ADXS: 7.18 (+0.06), GSK: 47.94 (+1.99), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Genmab's (GNMSF) CEO Jan Winkel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 1:16AM CST
Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma
GlobeNewswire - Mon Nov 10, 2:17AM CST
Company Announcement
GEN: 8.63 (+0.20)
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)
GlobeNewswire - Thu Nov 06, 8:46AM CST
Media Release
GEN: 8.63 (+0.20)
Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Thu Nov 06, 8:46AM CST
-- 13.4 month improvement in median progression free survival in patients receiving ofatumumab maintenance therapy for relapsed CLL
GEN: 8.63 (+0.20)
Genmab Announces Financial Results for the First Nine Months of 2014
GlobeNewswire - Wed Nov 05, 10:24AM CST
Interim Report for the Nine Months Ended September 30, 2014
Genmab Announces Conditional Transfer of Ofatumumab Agreement
GlobeNewswire - Mon Nov 03, 12:26AM CST
Company Announcement
GEN: 8.63 (+0.20), NVS: 102.20 (-0.17)
Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Thu Oct 23, 11:52AM CDT
Company Announcement
GEN: 8.63 (+0.20)
Third Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Oct 22, 6:05AM CDT
Company Announcement
GEN: 8.63 (+0.20)
OMT Grants Unlimited OmniRat, OmniMouse and OmniFlic License
Business Wire - Wed Oct 01, 10:22AM CDT
Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT's three OmniAb(TM) platforms, OmniRat(R), OmniMouse(R) and OmniFlic(TM).
GEN: 8.63 (+0.20)
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
GlobeNewswire - Wed Sep 10, 7:15AM CDT
Company Announcement
GEN: 8.63 (+0.20), SGEN: 31.57 (+0.36)
Major Shareholder Announcement
GlobeNewswire - Wed Feb 04, 4:58PM CST
Company Announcement
GEN: 8.63 (+0.20)
Fourth Quarter and Full Year 2014 Net Sales Figures for Arzerra (ofatumumab)
GlobeNewswire - Wed Feb 04, 6:05AM CST
Company Announcement
GEN: 8.63 (+0.20)
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/2n69ld/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects Scope - The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Relapsing Remitting Multiple Sclerosis (RRMS) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Relapsing Remitting Multiple Sclerosis (RRMS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - MedImmune, LLC - XenoPort, Inc. - Novartis AG - Actelion Ltd - Mitsubishi Tanabe Pharma Corporation - Octapharma AG - Teva Pharmaceutical Industries Limited - Genmab A/S - Merck KGaA - Antisense Therapeutics Limited - Opexa Therapeutics - Trophos SA - Allozyne - Amarna Therapeutics - Synthetic Biologics - Cognosci - RedHill Biopharm - Nuron Biotech - Neurotec Pharma SL - BIOCAD - AbbVie Inc. For more information visit http://www.researchandmarkets.com/research/2n69ld/relapsing
GSK: 47.94 (+1.99), XNPT: 6.69 (-0.21), OPXA: 0.71 (-0.03), SYN: 2.13 (+0.18), ABBV: 58.05 (+1.00), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
How Genmab (GNMSF) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Genmab is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/dsgsvz/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - Amgen Inc. - Sanofi - Eli Lilly and Company - Viralytics Ltd. - Genentech, Inc. - MedImmune, LLC - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Emergent BioSolutions Inc. - Lentigen Corporation - Amorfix Life Sciences Ltd. - Piramal Enterprises Limited - Celltrion, Inc. - Astellas Pharma Inc. - BioMarin Pharmaceutical Inc. - Richter Gedeon Nyrt. - Astex Pharmaceuticals, Inc. - Genmab A/S - Cyclacel Pharmaceuticals Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Bayer AG - Incyte Corporation - Merck KGaA - 4SC AG - Celldex Therapeutics, Inc. - Immunomedics, Inc. - TG Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/dsgsvz/chronic
BMRN: 100.76 (+1.98), CLDX: 20.97 (+0.53), CYCC: 0.62 (-0.01), IMMU: 3.84 (unch), EBS: 28.76 (-0.12), INCY: 75.94 (+0.28), TGTX: 13.13 (-0.19), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), CELGZ: 3.17 (-0.04)
Genmab to Receive $3 Million Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Fri Dec 12, 12:59PM CST
Genmab A/S (Copenhagen:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen"
, triggering a $3 million payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. GEN: 8.63 (+0.20)
Amgen Hopes Sentiment Swings Sweeter for Myeloma Drug at Key Blood Cancer Meeting
at The Street - Sat Dec 06, 10:00AM CST
Scientists and investors are getting their first detailed look this weekend at a large study of Amgen's multiple myeloma drug Kyprolis.
AMGN: 153.48 (+0.30), SNY: 49.42 (+0.82), CELG: 115.88 (+0.16)
Genmab Announces Phase II Study of Daratumumab in Non-Hodgkin's Lymphomas
GlobeNewswire - Thu Dec 04, 12:36AM CST
Company Announcement
GEN: 8.63 (+0.20)
Genmab Announces Phase II Study of Daratumumab in Smoldering Multiple Myeloma
GlobeNewswire - Mon Nov 24, 7:53AM CST
Company Announcement
GEN: 8.63 (+0.20)
Global Cervical Cancer Therapeutic Pipeline Review, H2 2014 - 35 Companies & 71 Drug Profiles
M2 - Wed Nov 19, 4:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/4p52hn/cervical_cancer) has announced the addition of the "Cervical Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cervical Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Sanofi - GlaxoSmithKline plc - Nektar Therapeutics - Inovio Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - Amorfix Life Sciences Ltd. - MediGene AG - Nanotherapeutics, Inc. - Arbor Vita Corporation - Novartis AG - Chong Kun Dang Pharmaceutical Corp. - Taiho Pharmaceutical Co., Ltd. - Zeria Pharmaceutical Co Ltd - Genmab A/S - Advaxis, Inc. - 3SBio Inc. - Transgene SA - Antigen Express, Inc. - Shantha Biotechnics Limited - Bionor Pharma ASA - Azaya Therapeutics Incorporated - Merrimack Pharmaceuticals, Inc. - Genexine, Inc. - Genticel - Sirnaomics, Inc. - EyeGene, Inc. - Vaccibody AS - Wellstat Biologics Corporation - ISA Pharmaceuticals B.V. For more information visit http://www.researchandmarkets.com/research/4p...cal_cancer
MACK: 10.22 (+0.40), INO: 6.80 (-0.15), ADXS: 7.18 (+0.06), GSK: 47.94 (+1.99), NKTR: 13.54 (-0.14), NVS: 102.20 (-0.17)
Genmab's (GNMSF) CEO Jan Winkel on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 1:16AM CST
Genmab Announces New Phase III Combination Study of Daratumumab in Frontline Multiple Myeloma
GlobeNewswire - Mon Nov 10, 2:17AM CST
Company Announcement
GEN: 8.63 (+0.20)
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH)
GlobeNewswire - Thu Nov 06, 8:46AM CST
Media Release
GEN: 8.63 (+0.20)
Genmab Announces Additional Data from Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Thu Nov 06, 8:46AM CST
-- 13.4 month improvement in median progression free survival in patients receiving ofatumumab maintenance therapy for relapsed CLL
GEN: 8.63 (+0.20)
Genmab Announces Financial Results for the First Nine Months of 2014
GlobeNewswire - Wed Nov 05, 10:24AM CST
Interim Report for the Nine Months Ended September 30, 2014
Genmab Announces Conditional Transfer of Ofatumumab Agreement
GlobeNewswire - Mon Nov 03, 12:26AM CST
Company Announcement
GEN: 8.63 (+0.20), NVS: 102.20 (-0.17)
Genmab Reaches USD 10 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Thu Oct 23, 11:52AM CDT
Company Announcement
GEN: 8.63 (+0.20)
Third Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Oct 22, 6:05AM CDT
Company Announcement
GEN: 8.63 (+0.20)
OMT Grants Unlimited OmniRat, OmniMouse and OmniFlic License
Business Wire - Wed Oct 01, 10:22AM CDT
Open Monoclonal Technology, Inc. (OMT), an innovator of novel genetic engineering of animals for creation of human therapeutic antibodies, today announced an alliance with Genmab A/S (OMX: GEN), a biotechnology company specializing in human antibody therapeutics. The deal gives Genmab unlimited access to OMT's three OmniAb(TM) platforms, OmniRat(R), OmniMouse(R) and OmniFlic(TM).
GEN: 8.63 (+0.20)
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
GlobeNewswire - Wed Sep 10, 7:15AM CDT
Company Announcement
GEN: 8.63 (+0.20), SGEN: 31.57 (+0.36)
